Secchi, Ottavio, Andrea Franchi, and Armando Lunello. 2023. “Comments to ‘Cost Per Responder for Vedolizumab and Ustekinumab in Crohn’s Disease Patients After Failure of TNF-α Inhibitors in Italy’”. AboutOpen 10 (1):82-86. https://doi.org/10.33393/ao.2023.2600.